

**ASX Announcement | 4 November 2021**  
**Visioneering Technologies (ASX:VTI)**

## **Visioneering Technologies Inc. Appoints Ashley Tuan, OD, PhD as Chief Medical Officer**

**Atlanta, Georgia, Thursday, 4 November 2021 (Sydney Friday, 5 November 2021):** US-based medical device company and producer of the NaturalVue® Multifocal 1 Day Contact Lenses ('NaturalVue MF') **Visioneering Technologies, Inc (ASX: VTI)** ('Visioneering', 'VTI' or 'the Company') is pleased to name Kuang-mon (Ashley) Tuan, OD, PhD, FAAO as Chief Medical Officer.

In her new position, Dr. Tuan will be responsible for managing clinical research studies, such as the NaturalVue® (etafilcon A) Multifocal randomized clinical trial for myopia progression control in children, helping identify and develop new products, and leading efforts to communicate findings in key journals and scientific meetings. Dr. Taun will also lead VTI's Professional Services team as it communicates technical information on products and initiatives to eye care professionals.

"VTI is working hard to build high strategic value in the Company and towards being a profitable independent provider of specialized eye care solutions. Dr. Tuan's impressive career history highlight our goal to seek out leaders in our industry to help us achieve these goals through innovation in areas such as myopia, and other challenging vision areas," said **Visioneering's CEO, Stephen Snowdy, PhD**. "We are proud to have Dr. Tuan join our team and look forward to the many contributions she will make to our organization as we seek to broaden our profile both geographically and through new product reach."

Dr. Tuan's professional career encompasses 27 years experience and includes a strong background in clinical and vision research in areas such as Myopia, Higher Order Aberrations, Presbyopia, Refractive Surgeries and Age-related Macular Degeneration. Most recently, as Vice-President of Mojo Vision, a smart contact lens company, Dr. Tuan focused on medical use cases and contact lens platform product strategy, contact lens system Research & Development with oversight of Clinical, Regulatory, Medical and Professional Affairs. While at CooperVision, Tuan was part of the team that delivered the 3-year study that enabled the launch of myopia control contact lenses, MiSight.



Dr. Tuan is a member of the Association for Research in Vision and Ophthalmology (ARVO), the British Contact Lens Association (BCLA) and is a Fellow of the American Academy of Optometry (FAAO). She obtained her Masters degree in Physiological Optics, her Doctor of Optometry degree from The Ohio State University, and her PhD in Vision Science from the University of California at Berkeley.

“I am thrilled to be joining VTI and returning to the field of Myopia Management. My career has been focused on translating research and technology to advancing various sectors of vision care,” said **Dr. Tuan**. “The vision care industry is entering a new evolution phase of complex and fascinating period of growth. Together with the VTI team, I am looking forward to the exciting journey of defining an ecosystem and delivering solutions for the Vision Care community with the goal of reducing the risk of myopia-related visual impairment globally.”

To contact Dr. Tuan directly call 1-844-VTI-LENS (1-844-884-5367), or email [ATuan@VTIVision.com](mailto:ATuan@VTIVision.com).

**Ends**

**This release was authorized by the CEO, Stephen Snowdy, PhD.**

**For more information, please contact:**

<b><i>Company</i></b>	<b><i>Investor and media relations</i></b>
Stephen Snowdy CEO, Visioneering Technologies, Inc. Email: <a href="mailto:ssnowdy@vtivision.com">ssnowdy@vtivision.com</a>	Haley Chartres H <sup>^</sup> CK Digital Tel: +61 423 139 163 Email: <a href="mailto:haley@hck.digital">haley@hck.digital</a>

### **About Visioneering Technologies**

Visioneering Technologies Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. Since its founding in 2008, Visioneering has brought together clinical, marketing, engineering, manufacturing, and regulatory leaders from top vision care businesses to provide new solutions for presbyopia, myopia, and astigmatism.

Headquartered in the US, Visioneering designs, manufactures, sells, and distributes contact lenses. Its flagship product is the NaturalVue<sup>®</sup> Multifocal contact lens, and VTI has expanded its portfolio of technologies to address a range of eye care issues. The company has grown operations across the United States, Australia, and Europe and is expanding into Asia with a focus on markets with high rates of myopia.

### **About the American Academy of Optometry**

The American Academy of Optometry (AAO) inspires excellence in optometric practice by fostering research and disseminating knowledge in vision science through its journal, Optometry, and Vision Science, and the continuing education presented at its annual meeting. Fellows of the Academy are committed to the premise that learning is a lifelong obligation of a professional, as is the commitment to expand the profession’s knowledge base through ongoing fellowship and exchange. For more information, visit the website: <http://www.aaopt.org>.

### **Foreign ownership restrictions**

VTI’s CHES Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers that are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are ‘restricted securities’ under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs

into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act, or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

### Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, <sup>i</sup> U.S. commercial market acceptance and U.S. sales of our product, as well as our expectations with respect to our ability to develop and commercialize new products.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

VTI-IR-ASX55

---